Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5458514 PSMA Targeting T Cell Engager Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06990880 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06990880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06990880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5458514 PSMA Targeting T Cell Engager Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2025
Completion date
August 9, 2028
Enrollment
85 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, prostate